HeartWare Schedules Fourth Quarter Conference Call and Webcast

        HeartWare Schedules Fourth Quarter Conference Call and Webcast

PR Newswire

FRAMINGHAM, Mass. and SYDNEY, Feb. 19, 2013

FRAMINGHAM, Mass. and SYDNEY, Feb. 19, 2013 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to
discuss its financial results for the three months ended December 31, 2012, at
8:30 a.m. U.S. Eastern Standard Time on Wednesday, February 27, 2013. The
Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial
results, highlights from the fourth quarter and business outlook. The call
may be accessed by dialing 1-888-846-5003 five minutes prior to the scheduled
start time and referencing "HeartWare." For callers outside the U.S., please
dial +1-480-629-9856.

A live webcast of the call will also be available at the Company's website
(www.heartware.com) by selecting "HeartWare Fourth Quarter 2012 Conference
Call" under the section titled "Corporate Presentations" on the Home Page. A
replay of the conference call will be available through the above weblink
immediately following completion of the call.

A copy of the news release announcing results and related information will be
available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable
heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The HeartWare® Ventricular Assist
System features the HVAD® pump, a small full-support circulatory assist device
designed to be implanted next to the heart, avoiding the abdominal surgery
generally required to implant competing devices. The HeartWare System is
approved in the United States for the intended use as a bridge to cardiac
transplantation in patients who are at risk of death from refractory end-stage
left ventricular heart failure, and has received CE Marking in the European
Union and has been used to treat patients in 27 international countries. The
device is also currently the subject of a U.S. clinical trial for destination
therapy. For additional information, please visit the Company's website at
www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its
securities are publicly traded on The NASDAQ Stock Market and the Australian
Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.

Website: http://www.heartware.com